What is LOPJLB’s current signal on SPRO?

LOPJLB’s latest quantitative signal on Spero Therapeutics, Inc. (SPRO) is SELL in a RECOVERY regime. Signals are updated daily.

What market regime is SPRO in?

Spero Therapeutics, Inc. (SPRO) is currently classified in the RECOVERY HMM market regime on LOPJLB.

What does Spero Therapeutics, Inc. (SPRO) do?

Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-c…

Spero Therapeutics, Inc. (SPRO)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$1.20+5.26%Close

SELLRECOVERY · day 1

Company news

invezz.com · 7d ago

Russian plague outbreak could boost these under-the-radar pharma stocks

globenewswire.com · 10d ago

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

globenewswire.com · 39d ago

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

globenewswire.com · 40d ago

Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

seekingalpha.com · 61d ago

Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript

marketbeat.com · 61d ago

Spero Therapeutics Q2 Earnings Call Highlights

globenewswire.com · 61d ago

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

globenewswire.com · 68d ago

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

globenewswire.com · 69d ago

Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

globenewswire.com · 77d ago

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

seekingalpha.com · 90d ago

Spero Therapeutics: 'Buy' On Utebzi Royalty Deal For Funding And SP001 In-Licensing

globenewswire.com · 90d ago

Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

prnewswire.com · 90d ago

Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

globenewswire.com · 90d ago

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

Market news & ticker search · RSS for SPRO

FAQ

What is LOPJLB’s current signal on SPRO?: LOPJLB’s latest quantitative signal on Spero Therapeutics, Inc. (SPRO) is SELL in a RECOVERY regime. Signals are updated daily.
What market regime is SPRO in?: Spero Therapeutics, Inc. (SPRO) is currently classified in the RECOVERY HMM market regime on LOPJLB.
What does Spero Therapeutics, Inc. (SPRO) do?: Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-c…

Spero Therapeutics, Inc. (SPRO)

Key stats

Prediction markets

Company news

FAQ